AlphaValue Corporate Services
This research has been commissioned and paid for by the company and is deemed to constitute an acceptable minor non-monetary benefit as defined in MiFID II

Crossject

CR
Bloomberg   ALCJ FP
Supergenerics  /  France  Web Site   |   Investors Relation
Things get going
Target
Upside 452%
Price (€) 2.08
Market Cap (€M) 75.8
Perf. 1W: -4.16%
Perf. 1M: -36.4%
Perf. 3M: -61.6%
Perf Ytd: -58.2%
10 day relative perf. to stoxx600: 1.54%
20 day relative perf. to stoxx600: -35.4%
EPS change31/08/2021

Change in EPS2021 : € -0.28 vs 0.18ns
2022 : € 0.63 vs 0.91-30.7%

We have fine-tuned our numbers on the back of the FY20 detailed accounts. Forecasts were also partly amended but net results remain low in the next few years which explains why a small change in the estimates translates into a more significant one in percentage terms at the EPS level.



Updates
.